fenfluramine has been researched along with Fatigue Syndrome, Chronic in 7 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Fatigue Syndrome, Chronic: A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that CFS is mediated by changes in hypothalamopituitary function and so measured the adrenocorticotrophic hormone (ACTH), cortisol, growth hormone, and prolactin responses to insulin-induced hypoglycemia, and the ACTH, cortisol, and prolactin responses to serotoninergic stimulation with dexfenfluramine in nondepressed CFS patients and normal controls." | 7.69 | Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. ( Allain, T; Bearn, J; Butler, J; Coskeran, P; McGregor, A; Munro, N; Wessely, S, 1995) |
| " We hypothesized that CFS is mediated by changes in hypothalamopituitary function and so measured the adrenocorticotrophic hormone (ACTH), cortisol, growth hormone, and prolactin responses to insulin-induced hypoglycemia, and the ACTH, cortisol, and prolactin responses to serotoninergic stimulation with dexfenfluramine in nondepressed CFS patients and normal controls." | 3.69 | Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. ( Allain, T; Bearn, J; Butler, J; Coskeran, P; McGregor, A; Munro, N; Wessely, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bearn, J | 2 |
| Allain, T | 2 |
| Coskeran, P | 1 |
| Munro, N | 1 |
| Butler, J | 1 |
| McGregor, A | 2 |
| Wessely, S | 2 |
| Yatham, LN | 1 |
| Morehouse, RL | 1 |
| Chisholm, BT | 1 |
| Haase, DA | 1 |
| MacDonald, DD | 1 |
| Marrie, TJ | 1 |
| Cleare, AJ | 3 |
| Murray, RM | 1 |
| O'Keane, V | 3 |
| Sharpe, M | 1 |
| Hawton, K | 1 |
| Clements, A | 1 |
| Cowen, PJ | 2 |
| Vassallo, CM | 1 |
| Feldman, E | 1 |
| Peto, T | 1 |
| Castell, L | 1 |
| Sharpley, AL | 1 |
| Miell, J | 1 |
| Heap, E | 1 |
| Sookdeo, S | 1 |
| Young, L | 1 |
| Malhi, GS | 1 |
1 trial available for fenfluramine and Fatigue Syndrome, Chronic
| Article | Year |
|---|---|
Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
Topics: Adrenocorticotropic Hormone; Adult; Analysis of Variance; Area Under Curve; Body Mass Index; Cortico | 2001 |
6 other studies available for fenfluramine and Fatigue Syndrome, Chronic
| Article | Year |
|---|---|
Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome.
Topics: Adrenocorticotropic Hormone; Adult; Fatigue Syndrome, Chronic; Female; Fenfluramine; Growth Hormone; | 1995 |
Neuroendocrine assessment of serotonin (5-HT) function in chronic fatigue syndrome.
Topics: Administration, Oral; Adult; Fatigue Syndrome, Chronic; Female; Fenfluramine; Humans; Hydrocortisone | 1995 |
Contrasting neuroendocrine responses in depression and chronic fatigue syndrome.
Topics: Adult; Depressive Disorder; Fatigue Syndrome, Chronic; Female; Fenfluramine; Humans; Hydrocortisone; | 1995 |
Re: Endocrine responses to fenfluramine challenge in chronic fatigue syndrome.
Topics: Comorbidity; Depressive Disorder; Fatigue Syndrome, Chronic; Fenfluramine; Humans; Hydrocortisone; P | 1996 |
Increased brain serotonin function in men with chronic fatigue syndrome.
Topics: Adult; Brain; Fatigue Syndrome, Chronic; Fenfluramine; Humans; Male; Norfenfluramine; Prolactin; Ser | 1997 |
Decreased tryptophan availability but normal post-synaptic 5-HT2c receptor sensitivity in chronic fatigue syndrome.
Topics: Adult; Fatigue Syndrome, Chronic; Female; Fenfluramine; Humans; Male; Middle Aged; Piperazines; Prol | 2001 |